menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission Engineered cell therapy platform will enable wholly owned development candidate for acute
Read More

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed Fred Cohen , M.D., D.Phil, F.A.C.P., to its board of
Read More

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing
Read More

Intellia Therapeutics to Present at November Healthcare Investor Conferences

CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
Read More

Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments

Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its lead transthyretin
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments

CAMBRIDGE, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2018 results and corporate developments in
Read More

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer

CAMBRIDGE, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has named Glenn Goddard its executive vice president and chief
Read More

Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy

Intellia scientists present first robust demonstration of CRISPR-mediated insertion of  transgenes in the liver Non-human primate data show high correlation achieved between  liver edit and reduction of TTR protein High rate and specificity of acute myeloid leukemia cell killing observed  with
Read More

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in October: Monday,
Read More

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells   University of California/University of Vienna /Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology
Read More
RSS FEEDS
PRINT PAGE